Advertisement

Topics

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

01:08 EST 22nd February 2017 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

Adjuvant Bevacizumab for Colorectal Cancer?

Adding bevacizumab to capecitabine did not improve survival for patients with stage III or high-risk stage II disease.


Colorectal Cancer: Isofol’s Modufolin Could Change Mainstay Therapy

Decades-long academic and pharma research to improve on the benefits of the 5-fluorouracil and Leucovorin combination in colorectal cancer has...   

Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer

A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks.


Therapy: No benefit for adjuvant capecitabine plus bevacizumab in colorectal cancer

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

FDA approves bevacizumab with chemotherapy for platinum-sensitive ovarian cancer

The U.S. Food and Drug Administration (FDA) has approved bevacizumab, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by bevacizumab alone, for the treatment of patients with...

BRIEF-Amgen says new retrospective analyses confirm Vectibix treatment provided survival benefit over chemotherapy with or without Bevacizumab

* New retrospective analyses confirm Vectibix (panitumumab) treatment provided survival benefit over chemotherapy with or without bevacizumab in metastatic colorectal cancer patients with tumors of left-sided origin Source text for Eikon: Further ...

Liquid Biopsy and Colorectal Cancer

A liquid biopsy option for potential colorectal cancer patients. Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90%, but only approximately four out of 10 CRC cases [...]

Medical News Today: Colorectal cancer screening initiative shows promise

The Ohio State University have trialed a colorectal cancer screening initiative for relatives of colorectal cancer patients. The results are promising.

CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC

This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.

Fecal Fat Points to Early Presence of Colorectal Cancer

Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, and therefore more accessible screening tests are urgently needed...

Blood Test for Colorectal Cancer Recurrence Proves Highly Sensitive

When diagnosed early, before cancer has spread, the relative five-year survival rate for colorectal cancer (CRC) is 90%, but only...

Bevacizumab for Extensive-Stage Small-Cell Lung Cancer

Adding bevacizumab to cisplatin and etoposide improved progression-free survival, but not overall survival, the primary outcome.

Metabolite that promotes cancer cell transformation and colorectal cancer spread identified

Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial–mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against...

FDA Approves Avastin® (Bevacizumab) Plus Chemotherapy for Treatment of Advanced Ovarian Cancer

Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Women are said to...

Clinical Genomics’ blood test detects twice the number of colorectal cancer recurrence cases than CEA testing

Clinical Genomics, a private company developing innovative diagnostic tools for colorectal cancer, today announced that data supporting its two-gene circulating tumor DNA (ctDNA) blood test for post-surgical monitoring of colorectal cancer (CRC) recurrence have been published online by Cancer Medicine, and will appear in the October issue.

NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer

SIR-Spheres® Y-90 microspheres have just been added as a new treatment option in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. Nearly 140,000 Americans are diagnosed with colorectal cancer every year1, and more than 50% will have their cancer spread to their liver.2 This gives patients with cancer [̷...

Study Tightens Connection between Intestinal Microorganisms, Diet, and Colorectal Cancer

Prudent diets appear to protect against colorectal cancer

New developments in advanced colorectal cancer

San Francisco: ASCO Gastrointestinal symposium 2017 – Update on metastatic colorectal cancer It might surprise quite a few people that…

Relevant

BRIEF-Genentech- says U.S. FDA has approved Avastin Bevacizumab

* FDA approves Genentech's Avastin (Bevacizumab) plus chemotherapy for a specific type of advanced ovarian cancer Source text for Eikon: Further company coverage:

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Poor responses of liver metastases to the anti-angiogenic agent bevacizumab in colorectal and breast cancer patients correlate with tumor co-option of pre-existing blood vessels, a mechanism of tumor resistance that might be targeted by inhibition of cancer cell motility.

Bevacizumab Combination Improves PFS, but Not OS, in Extensive-Disease SCLC

The addition of bevacizumab to a first-line regimen of cisplatin and etoposide improved progression-free survival in patients with extensive-disease small-cell lung cancer.

FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer

South San Francisco, CA -- December 6, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab), either in combination with...


Quick Search
Advertisement
 

News Quicklinks